| Management target | Revenue 18.0% FY27 |
|---|
| Revenue growth | 25% YoY; US led growth while Asia declined due to logistics. |
|---|---|
| Margins | Gross margin at 80%; full-year EBITDA guided at 27% excluding forex. |
| Demand visibility | Strong domestic demand in cardiology and ophthalmology; Asia demand remains high. |
| Management confidence | Confident in domestic/Africa; conservative on US normalization and Asia recovery. |
Growth
Revenue grew 25% YoY; US generics spiked 57% due to carryover and new launches.
Outlook
EBITDA margin guidance 27% (±100bps); full-year US growth guided at mid-single digits despite Q1 beat.
Risks
Middle East geopolitical issues disrupting Asia supply chain; US price erosion expected to normalize.
Earnings Call Transcript filed with BSE, NSE: AJANTPHARM. Summary written with AI assistance from the document.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,573.90
- Market cap
- ₹44,659 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 39.4×Sector 47.4×
- Promoter holding
- 63.48%-2.77% QoQ
- FII holding
- 7.68%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Share Pledge
Aayush Agrawal (Trustee of Aayush Agrawal Trust) has released a pledge on 1,736,353 equity shares of Ajanta Pharma Limited. This follows loan repayment.
Ajanta Pharma Share Pledge
Promoter Aayush Agrawal Trust released pledge on 9.76 lakh shares and created a new pledge on 9.20 lakh shares of Ajanta Pharma Limited.
Ajanta Pharma Share Pledge
Promoter Ravi Agrawal, as trustee of Ravi Agrawal Trust, released a pledge on 54,796 equity shares of Ajanta Pharma Limited due to excess pledge.
Ajanta Pharma Employee Stock Options
Ajanta Pharma Limited has allotted 23,400 equity shares following the exercise of employee stock options. Consequently, the company's paid-up share capital increased to Rs. 24.99 Crore.
Ajanta Pharma Dividend
Ajanta Pharma Limited has fixed August 5, 2026, as the record date. This date determines shareholder eligibility for the payment of the first interim dividend.
Ajanta Pharma Q1 FY27 Results: Net Profit ₹334.2 Cr, Up 30.9% YoY
Ajanta Pharma Ltd reported revenue from operations of ₹1,626 Cr (+24.8% YoY) and net profit of ₹334.2 Cr (+30.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹334.2 Cr · +30.9% YoY